WALD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. WALD just surged (~13.5% regular session) into near-term resistance (R1 1.848) and the short-horizon pattern stats skew to a mild pullback over the next day/week. With no Intellectia buy signals and mixed analyst sentiment following weak results/guidance, an impatient buyer is more likely to face an unfavorable entry at current levels.
Price/Trend: Strong one-day upside move (close 1.825 vs 1.595) pushing into resistance. Momentum: MACD histogram +0.026 and expanding (bullish momentum). RSI(6): 67.09 (upper-neutral/approaching overbought), suggesting upside may be getting crowded short-term. Moving Averages: Converging MAs (no clean established trend; transition phase). Key Levels: Pivot 1.677; Resistance R1 1.848 (very close), R2 1.954; Support S1 1.506, S2 1.40. Pattern-based forward look: 60% chance of about -1.04% next day and -1.36% next week, with +7.27% next month (near-term digestion risk despite potential monthly upside).
Intellectia Proprietary Trading Signals:
Obagi Medical partnership with VIO Med Spa (ALOHA Program) could support brand visibility and longer-term demand; MACD turning positive supports a near-term momentum narrative; potential 1-month upside indicated by pattern stats (+7.27%).
after a sharp jump—higher odds of short-term pullback; analyst commentary highlights prior quarter disappointments and Milk Makeup weakness/out-of-stocks; FY25 sales expected broadly in-line with FY24 (limited growth catalyst); no hedge fund/insider accumulation signal noted.
Latest provided quarter: 2025/Q1. Revenue 65.44M (flat YoY per data), net income 0 (flat), EPS -1.51 (flat), gross margin 69.91% (flat). Overall, the snapshot shows no clear acceleration in growth versus last year in the provided figures.
Recent trend: Ratings/targets turned more cautious. Canaccord kept Buy but cut PT to $4 from $5; Telsey downgraded to Market Perform from Outperform with a $3 PT after disappointing Q2 and reduced FY25 outlook. Wall Street pros: Bulls point to brand portfolio and potential normalization after operational issues; bears emphasize execution risk (Milk Makeup), below-expectation quarters, and tempered FY25 growth outlook. Politicians/Congress: No recent congress trading data available; no notable politician activity provided.
